The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma, showed that MRI detected invasive breast tumors at very early stages, when cure rates are expected to be excellent.
New data show a high prevalence of coronary artery disease among survivors of Hodgkin lymphoma.
Patients with Hodgkin lymphoma who have PET-positive residual disease after chemotherapy and poor tumor shrinkage are at high risk of progression or relapse.
Girls treated for Hodgkin’s lymphoma during adolescence acquire a considerable risk of developing breast cancer.
The FDA has granted nivolumab (Bristol-Myers Squibb) Breakthrough Therapy designation for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Specific Hodgkin lymphoma treatments consisting of high-dose radiation and chemotherapy are associated with an 80-fold higher risk of stomach cancer.
The FDA has accepted Seattle Genetics’ sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Among patients treated for Hodgkin lymphoma , long-term excess mortality due to diseases of the circulatory system is expected to continue to decline.
